[go: up one dir, main page]

ME02858B - Formulacija za anti- 4 7 antitelo - Google Patents

Formulacija za anti- 4 7 antitelo

Info

Publication number
ME02858B
ME02858B MEP-2017-227A MEP2017227A ME02858B ME 02858 B ME02858 B ME 02858B ME P2017227 A MEP2017227 A ME P2017227A ME 02858 B ME02858 B ME 02858B
Authority
ME
Montenegro
Prior art keywords
seq
stable liquid
pharmaceutical formulation
liquid pharmaceutical
formulation according
Prior art date
Application number
MEP-2017-227A
Other languages
German (de)
English (en)
French (fr)
Inventor
Willow Diluzio
Phuong M Nguyen
Csanad M Varga
Vaithianathan Palaniappan
Jason Brown
Irving H Fox
Catherine Scholz
Erica Helen Jenkins
Maria Rosario
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02858(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ME02858B publication Critical patent/ME02858B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)

Claims (31)

1.  Stabilna tečna farmaceutska formulacija koja obuhvata anti-α4β7 antitelo, citrat, i najmanje jednu slobodnu aminokiselinu, pri čemu anti-α4β7 antitelo obuhvata varijabilan region lakog lanca koji obuhvata region 1 koji određuje komplementarnost (CDR1) koji obuhvata SEQ ID NO:11, CDR2 koji obuhvata SEQ ID NO:12, i CDR3 koji obuhvata SEQ ID NO:13, i obuhvata varijabilan region teškog lanca koji obuhvata CDR1 koji obuhvata SEQ ID NO:8, CDR2 koji obuhvata SEQ ID NO:9, i CDR3 koji obuhvata SEQ ID NO:10.
2.  Stabilna tečna farmaceutska formulacija prema zahtevu 1, u kojoj je molarni odnos anti-α4β7 antitela prema citratu oko 1:4 do oko 1:100.
3.  Stabilna tečna farmaceutska formulacija prema zahtevu 1 ili 2, u kojoj je pomenuta slobodna aminokiselina odabrana iz grupe koju čine histidin, alanin, arginin, glicin, glutaminska kiselina i njihove kombinacije.
4.  Stabilna tečna formulacija prema bilo kom od prethodnih zahteva, koja dalje obuhvata neki surfaktant.
5.  Stabilna tečna farmaceutska formulacija prema zahtevu 4, u kojoj je molarni odnos citrata prema surfaktantu oko 3:1 do oko 156:1.
6.  Stabilna tečna formulacija prema zahtevu 4 ili 5, u kojoj surfaktant predstavlja polisorbat 20, polisorbat 80, poloksamer i njihove kombinacije.
7.  Stabilna tečna formulacija prema zahtevu 6, u kojoj surfaktant predstavlja polisorbat 80, a koncentracija polisorbata 80 je 0,01% do 0,5%.
8.  Stabilna tečna farmaceutska formulacija prema bilo kom od zahteva 1-7, u kojoj je koncentracija citrata 5 mM do 50 mM.
9.  Stabilna tečna farmaceutska formulacija koja obuhvata najmanje oko 60 mg/ml do oko 190 mg/ml anti-α4β7 antitela, antioksidans ili helator, i najmanje jednu slobodnu aminokiselinu, pri čemu anti-α4β7 antitelo obuhvata varijabilan region lakog lanca koji obuhvata region 1 koji određuje komplementarnost (CDR1) koji obuhvata SEQ ID NO:11, CDR2 koji obuhvata SEQ ID NO:12, i CDR3 koji obuhvata SEQ ID NO:13, i obuhvata varijabilan region teškog lanca koji obuhvata CDR1 koji obuhvata SEQ ID NO:8, CDR2 koji obuhvata SEQ ID NO:9, i CDR3 koji obuhvata SEQ ID NO:10.
10. Stabilna tečna farmaceutska formulacija koja obuhvata anti-α4β7 antitelo, antioksidans ili helator, i najmanje jednu slobodnu aminokiselinu, pri čemu anti-α4β7 antitelo obuhvata varijabilan region lakog lanca koji obuhvata region1 koji određuje komplementarnost (CDR1) koji obuhvata SEQ ID NO:11, CDR2 koji obuhvata SEQ ID NO:12, i CDR3 koji obuhvata SEQ ID NO:13, i obuhvata varijabilan region teškog lanca koji obuhvata CDR1 koji obuhvata SEQ ID NO:8, CDR2 koji obuhvata SEQ ID NO:9, i CDR3 koji obuhvata SEQ ID NO:10, i gde formulacija ima pH od 6,1 do 7,0.
11.  Stabilna tečna farmaceutska formulacija prema zahtevu 9 ili 10, koja obuhvata oko 150 mg/ml do oko 180 mg/ml anti-α4β7 antitela.
12. Stabilna tečna farmaceutska formulacija prema zahtevu 9 ili 10, u kojoj antioksidans ili helator predstavlja citrat ili EDTA.
13. Stabilna tečna farmaceutska formulacija prema zahtevu 12, u kojoj antioksidans ili helator predstavlja citrat.
14. Stabilna tečna farmaceutska formulacija prema zahtevu 13, u kojoj je koncentracija citrata 5 mM do 50 mM.
15. Stabilna tečna farmaceutska formulacija prema bilo kom od zahteva 9-15, koja dalje obuhvata neki surfaktant.
16. Stabilna tečna farmaceutska formulacija prema zahtevu 15, u kojoj je molarni odnos surfaktant:antitelo od oko 0,7:1 do oko 2,0:1.
17. Stabilna tečna farmaceutska formulacija prema zahtevu 15, u kojoj je molarni odnos antioksidansa ili helatora prema surfaktantu oko 3:1 do oko 156:1.
18. Stabilna tečna farmaceutska formulacija prema zahtevu 15, u kojoj surfaktant predstavlja polisorbat 20, polisorbat 80, poloksamer i njihove kombinacije.
19. Stabilna tečna farmaceutska formulacija prema zahtevu 18, u kojoj surfaktant predstavlja polisorbat 80, a koncentracija polisorbata 80 je 0,01% do 0,5%.
20. Stabilna tečna farmaceutska formulacija prema zahtevu 9 ili 10, koja obuhvata anti-α4β7 antitelo, citrat, histidin, arginin, i polisorbat 80, pri čemu anti-α4β7 antitelo obuhvata varijabilan region lakog lanca koji obuhvata region1 koji određuje komplementarnost (CDR1) koji obuhvata SEQ ID NO:11, CDR2 koji obuhvata SEQ ID NO:12, i CDR3 koji obuhvata SEQ ID NO:13, i obuhvata varijabilan region teškog lanca koji obuhvata CDR1 koji obuhvata SEQ ID NO:8, CDR2 koji obuhvata SEQ ID NO:9, i CDR3 koji obuhvata SEQ ID NO:10.
21. Stabilna tečna farmaceutska formulacija prema zahtevu 20, u kojoj je koncentracija anti-α4β7 antitela najmanje oko 140 mg/ml.
22. Stabilna tečna farmaceutska formulacija prema zahtevu 20 ili 21, u kojoj je koncentracija histidina 10 mM do 75 mM.
23. Stabilna tečna farmaceutska formulacija prema bilo kom od zahteva 20-21, u kojoj je koncentracija arginina 50 mM do 150 mM.
24. Stabilna tečna farmaceutska formulacija prema bilo kom od zahteva 20 - 23, u kojoj je koncentracija citrata 5 mM do 50 mM.
25. Stabilna tečna farmaceutska formulacija prema bilo kom od zahteva 1-24, u kojoj antitelo obuhvata varijabilan region teškog lanca koji obuhvata aminokiseline 20-140 iz SEQ ID NO: 2 i varijabilan region lakog lanca koji obuhvata aminokiseline 20-131 iz SEQ ID NO:4 ili aminokiseline 21-132 iz SEQ ID NO:5.
26. Stabilna tečna farmaceutska formulacija prema bilo kom od prethodnih zahteva, u kojoj pomenuto antitelo predstavlja vedolizumab.
27. Proizvod proizvodnje koji obuhvata kontejner, stabilnu tečnu farmaceutsku formulaciju prema bilo kom od zahteva 1-26, i instrukcije za njenu upotrebu.
28. Proizvod prema zahtevu 27, u kom pomenuta stabilna tečna farmaceutska formulacija obuhvata 108 mg antitela.
29. Proizvod prema zahtevu 27, pri čemu proizvod predstavlja prethodno napunjen špric.
30. Stabilna tečna farmaceutska formulacija prema bilo kom od zahteva 1-26 ili proizvod proizvodnje prema bilo kom od zahteva 27 do 29 za upotrebu u lečenju zapaljenske bolesti creva.
31. Stabilna tečna farmaceutska formulacija ili proizvod proizvodnje prema zahtevu 30, pri čemu zapaljenska bolest creva predstavlja Kronovu bolest ili ulcerozni kolitis. 
MEP-2017-227A 2011-05-02 2012-05-02 Formulacija za anti- 4 7 antitelo ME02858B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161481522P 2011-05-02 2011-05-02
US201161544054P 2011-10-06 2011-10-06
PCT/US2012/036069 WO2012151247A2 (en) 2011-05-02 2012-05-02 FORMULATION FOR ANTI-α4β7 ANTIBODY
EP12722973.0A EP2704742B1 (en) 2011-05-02 2012-05-02 Formulation for anti- 4 7 antibody

Publications (1)

Publication Number Publication Date
ME02858B true ME02858B (me) 2018-04-20

Family

ID=46147702

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-227A ME02858B (me) 2011-05-02 2012-05-02 Formulacija za anti- 4 7 antitelo

Country Status (38)

Country Link
US (7) US10040855B2 (me)
EP (5) EP3311834A1 (me)
JP (6) JP6190359B2 (me)
KR (8) KR101884406B1 (me)
CN (4) CN108969469A (me)
AR (1) AR086238A1 (me)
AU (5) AU2012250872B2 (me)
CA (2) CA3051418C (me)
CL (3) CL2013003145A1 (me)
CO (1) CO6801648A2 (me)
CR (1) CR20130556A (me)
CY (1) CY1119436T1 (me)
DK (1) DK2704742T3 (me)
DO (1) DOP2013000252A (me)
EA (1) EA032625B1 (me)
EC (1) ECSP22046340A (me)
ES (1) ES2646717T3 (me)
GE (2) GEAP201813302A (me)
HK (1) HK1253911A1 (me)
HR (1) HRP20171457T1 (me)
HU (1) HUE036664T2 (me)
IL (6) IL274846B2 (me)
LT (1) LT2704742T (me)
ME (1) ME02858B (me)
MX (4) MX354101B (me)
MY (1) MY188820A (me)
PE (1) PE20141672A1 (me)
PH (3) PH12013502237A1 (me)
PL (1) PL2704742T3 (me)
PT (1) PT2704742T (me)
RS (1) RS56429B1 (me)
SG (1) SG194730A1 (me)
SI (1) SI2704742T1 (me)
SM (1) SMT201700515T1 (me)
TW (5) TWI723339B (me)
UY (1) UY34054A (me)
WO (1) WO2012151247A2 (me)
ZA (2) ZA201308168B (me)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
ES2688093T3 (es) 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
MY158130A (en) * 2010-10-06 2016-08-30 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
PH12013501576A1 (en) 2011-01-28 2013-09-30 Sanofi Biotechnology Pharmaceutical compositions comprising human antibodies to pcsk9
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AU2012250872B2 (en) * 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
WO2013006810A1 (en) 2011-07-06 2013-01-10 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9764093B2 (en) * 2012-11-30 2017-09-19 Sio2 Medical Products, Inc. Controlling the uniformity of PECVD deposition
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
US10857090B2 (en) * 2013-07-05 2020-12-08 Stellar Biome Inc. Oral compositions
WO2015080513A1 (en) * 2013-11-29 2015-06-04 Hanwha Chemical Corporation A liquid formulation of a fusion protein comprising tnfr and fc region
JP6845012B2 (ja) 2014-01-21 2021-03-17 ダイアックス コーポレーション 遺伝性血管浮腫の治療における血漿カリクレイン結合タンパク質およびその使用
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
EP3204424B1 (en) 2014-10-06 2023-11-29 ChemoCentryx, Inc. Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
CA2968915A1 (en) 2014-12-03 2016-06-09 Csl Behring Ag Pharmaceutical product with increased stability comprising immunoglobulins
CN107250798A (zh) * 2014-12-05 2017-10-13 雀巢产品技术援助有限公司 用于检测患者样品中的生物制品的间接均相迁移率变动试验
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
EA201792161A1 (ru) * 2015-03-30 2018-04-30 Дайэкс Корп. Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
CA2994447A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
SG11201804961UA (en) * 2015-12-30 2018-07-30 Genentech Inc Formulations with reduced degradation of polysorbate
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
EA201892071A1 (ru) 2016-03-14 2019-03-29 Милленниум Фармасьютикалз, Инк. Способ профилактики болезни "трансплантат против хозяина"
CN109153721A (zh) 2016-03-14 2019-01-04 千禧制药公司 治疗或预防移植物抗宿主疾病的方法
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
EP3452070A1 (en) 2016-05-04 2019-03-13 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating inflammatory bowel disease
EP3468597A1 (en) 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
BR112019011900A2 (pt) * 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
CN108686204A (zh) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 包含组氨酸缓冲体系的英夫利西单抗组合物
EP3615071A2 (en) * 2017-04-28 2020-03-04 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)
CN111278863A (zh) * 2017-08-25 2020-06-12 奥默罗斯公司 高浓缩低粘度masp-2抑制性抗体制剂、试剂盒和治疗患有非典型溶血综合征的受试者的方法
SG11202009874QA (en) * 2018-04-10 2020-11-27 Dr Reddys Laboratories Ltd Antibody formulation
US12024561B2 (en) * 2018-04-10 2024-07-02 Dr. Reddy's Laboratories Limited Stable antibody formulation
US12433947B2 (en) 2018-04-10 2025-10-07 Dr. Reddy's Laboratories Limited Stable formulations of therapeutic antibody
EP3843783A1 (en) * 2018-08-29 2021-07-07 GlaxoSmithKline Intellectual Property Development Limited Methods of preparing stable liquid therapeutic protein compositions
EP3908276B1 (en) * 2019-01-08 2025-06-11 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
MA55735A (fr) * 2019-04-17 2022-02-23 Millennium Pharm Inc Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23
AR119268A1 (es) * 2019-06-10 2021-12-09 Millennium Pharm Inc Métodos de purificación de anticuerpos y composiciones de estos
WO2021070203A1 (en) * 2019-10-11 2021-04-15 Dr. Reddy's Laboratories Limited Stable formulation of integrin antibody
WO2021146160A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021223719A1 (zh) * 2020-05-08 2021-11-11 亘喜生物科技（上海）有限公司 一种抗cd19抗体的抗体及其制备和应用
TW202222832A (zh) * 2020-07-31 2022-06-16 美商建南德克公司 抗整聯蛋白β７抗體調配物及裝置
US20230340131A1 (en) * 2020-11-12 2023-10-26 Dr. Reddy’S Laboratories Limited Stable aqueous high concentration formulation of integrin antibody
US20240101679A1 (en) * 2020-12-09 2024-03-28 Dr. Reddy’S Laboratories Limited Stable aqueous buffer free formulation of an integrin antibody
WO2022253994A1 (en) * 2021-06-04 2022-12-08 Polpharma Biologics S.A. Vedolizumab formulation
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
US20250092141A1 (en) 2021-12-27 2025-03-20 Polpharma Biologics S.A. Vedolizumab formulation
CN119584985A (zh) * 2022-05-27 2025-03-07 索尼特生物治疗公司 Il-12-白蛋白结合结构域融合蛋白制剂及其使用方法
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
WO2025041000A1 (en) * 2023-08-21 2025-02-27 Intas Pharmaceuticals Ltd. STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-α4β7 ANTIBODY
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods
WO2025177055A1 (en) * 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Combination therapy for treating inflammatory bowel disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0303463B1 (en) 1987-08-11 1994-11-30 The Board Of Trustees Of The Leland Stanford Junior University Method to control leukocyte extravasation
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
WO1990007321A2 (en) 1988-12-23 1990-07-12 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte receptor homing sequences and their uses
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL95501A (en) 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
EP0625912B1 (en) 1992-02-12 1997-04-16 Biogen, Inc. Treatment for inflammatory bowel disease
WO1993023526A1 (en) 1992-05-21 1993-11-25 Center For Blood Research, Inc. A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
WO1994016094A2 (en) 1993-01-12 1994-07-21 Biogen, Inc. Recombinant anti-vla4 antibody molecules
AU687790B2 (en) 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
DE69535133T2 (de) 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
ES2290955T3 (es) 1995-02-10 2008-02-16 Millennium Pharmaceuticals, Inc. Adresinas vasculares de mucosas y sus usos.
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6189195B1 (en) 1995-08-22 2001-02-20 Medrad, Inc. Manufacture of prefilled syringes
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
EP3674322A1 (en) 2002-02-25 2020-07-01 Biogen MA Inc. Administration of agents for the treatment of inflammation
EP2402309A1 (en) 2002-05-24 2012-01-04 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
ATE363470T1 (de) 2002-11-18 2007-06-15 Chemocentryx Inc Arylsulfonamide
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US6886838B1 (en) 2003-01-22 2005-05-03 Zimmco Easy dumping cart
CA2517310C (en) 2003-02-28 2015-11-24 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations comprising a poloxamer
EP3178492A1 (en) 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
RU2453558C2 (ru) 2004-09-03 2012-06-20 Дженентек, Инк. Гуманизированные антагонистические антитела против бета7 и их применение
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3495009B2 (en) 2005-01-24 2025-01-15 Antares Pharma, Inc. An injector with prefilled syringe
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders
AU2006316629A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
KR101317235B1 (ko) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
AR064220A1 (es) * 2006-12-11 2009-03-18 Hoffmann La Roche Formulacion liofilizada mab abeta
US9111016B2 (en) 2007-07-06 2015-08-18 Stereotaxis, Inc. Management of live remote medical display
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
BRPI0819932A2 (pt) * 2007-12-13 2019-07-30 Glaxo Group Ltd composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável.
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2009099641A2 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
KR101391472B1 (ko) 2009-03-20 2014-05-07 암젠 인크 알파-4-베타-7 이종이량체 특이적 길항제 항체
WO2010121141A1 (en) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
CN101533504A (zh) * 2009-04-27 2009-09-16 刘文祥 电子医务系统及其装置
US9795674B2 (en) 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
AU2012250872B2 (en) 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3452070A1 (en) 2016-05-04 2019-03-13 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating inflammatory bowel disease

Also Published As

Publication number Publication date
PH12018502221A1 (en) 2019-10-28
IL229169B (en) 2020-06-30
CR20130556A (es) 2014-03-05
TWI638661B (zh) 2018-10-21
CL2017000829A1 (es) 2017-12-29
IL272237B (en) 2022-05-01
IL305583B1 (en) 2025-12-01
AU2017204192A1 (en) 2017-07-13
KR102493433B1 (ko) 2023-01-27
EP4403579B1 (en) 2025-12-10
EP4403579A3 (en) 2024-10-16
TWI723339B (zh) 2021-04-01
US20210340261A1 (en) 2021-11-04
EA201391613A1 (ru) 2014-07-30
PH12019501662A1 (en) 2021-03-15
ECSP22046340A (es) 2022-07-29
MX2013012725A (es) 2013-12-06
TWI832619B (zh) 2024-02-11
KR20190100451A (ko) 2019-08-28
KR101875155B1 (ko) 2018-07-09
PL2704742T3 (pl) 2018-01-31
EP2704742B1 (en) 2017-07-12
KR102136208B1 (ko) 2020-07-21
JP2020180163A (ja) 2020-11-05
TWI698254B (zh) 2020-07-11
IL274846B1 (en) 2024-12-01
EP4378959A2 (en) 2024-06-05
GEP20186866B (en) 2018-06-25
US20180346578A1 (en) 2018-12-06
CA3051418A1 (en) 2012-11-08
MX367097B (es) 2019-08-05
KR20230021758A (ko) 2023-02-14
CN107998388B (zh) 2023-07-14
CL2013003145A1 (es) 2014-07-25
DK2704742T3 (en) 2017-10-23
DOP2013000252A (es) 2013-12-31
WO2012151247A2 (en) 2012-11-08
CA3051418C (en) 2021-05-18
CY1119436T1 (el) 2018-03-07
AU2019216679B2 (en) 2021-09-23
TW202317193A (zh) 2023-05-01
ES2646717T3 (es) 2017-12-15
MX354101B (es) 2018-02-13
JP6751450B2 (ja) 2020-09-02
SG194730A1 (en) 2013-12-30
IL274846B2 (en) 2025-04-01
US12286479B2 (en) 2025-04-29
NZ617340A (en) 2015-12-24
EP4438625A2 (en) 2024-10-02
US20250034263A1 (en) 2025-01-30
EA201391613A8 (ru) 2016-05-31
JP2019052191A (ja) 2019-04-04
KR101884406B1 (ko) 2018-08-02
MX384203B (es) 2025-03-14
KR20210120144A (ko) 2021-10-06
AU2012250872A1 (en) 2013-11-21
EP4403579A2 (en) 2024-07-24
JP2014515763A (ja) 2014-07-03
KR102014512B1 (ko) 2019-08-26
US20200377601A1 (en) 2020-12-03
US11560434B2 (en) 2023-01-24
EP3311834A1 (en) 2018-04-25
IL290848A (en) 2022-04-01
HK1253911A1 (en) 2019-07-05
IL229169A0 (en) 2013-12-31
TW202434293A (zh) 2024-09-01
IL290849A (en) 2022-04-01
SI2704742T1 (sl) 2017-12-29
UY34054A (es) 2012-11-30
EP2704742A2 (en) 2014-03-12
AR086238A1 (es) 2013-11-27
KR20180080354A (ko) 2018-07-11
ZA201707310B (en) 2022-04-28
PH12013502237A1 (en) 2014-01-06
JP2025061332A (ja) 2025-04-10
CO6801648A2 (es) 2013-11-29
PH12018502221B1 (en) 2023-05-10
KR20250093426A (ko) 2025-06-24
EP4438625A3 (en) 2024-12-11
WO2012151247A3 (en) 2013-02-28
RS56429B1 (sr) 2018-01-31
TWI799757B (zh) 2023-04-21
EP4378959A3 (en) 2024-09-04
CN103533959A (zh) 2014-01-22
LT2704742T (lt) 2017-10-25
US10040855B2 (en) 2018-08-07
HUE036664T2 (hu) 2018-07-30
AU2023274233A1 (en) 2023-12-21
TW201813665A (zh) 2018-04-16
PT2704742T (pt) 2017-11-15
AU2017204192B2 (en) 2019-09-12
IL274846A (en) 2020-07-30
GEAP201813302A (en) 2018-02-26
AU2012250872B2 (en) 2017-07-13
KR102493433B9 (ko) 2023-09-01
CN103533959B (zh) 2018-06-05
MX2021008112A (es) 2022-06-02
JP7107997B2 (ja) 2022-07-27
AU2021225160A1 (en) 2021-09-30
CL2020001579A1 (es) 2020-11-06
JP6467457B2 (ja) 2019-02-13
CN107998388A (zh) 2018-05-08
TW202133878A (zh) 2021-09-16
KR20200088517A (ko) 2020-07-22
HRP20171457T1 (hr) 2017-11-03
US20230312727A1 (en) 2023-10-05
US20180327497A1 (en) 2018-11-15
JP2017137353A (ja) 2017-08-10
JP2022132430A (ja) 2022-09-08
US20140341885A1 (en) 2014-11-20
KR20140145952A (ko) 2014-12-24
KR102308938B1 (ko) 2021-10-01
TW201300128A (zh) 2013-01-01
KR20170056713A (ko) 2017-05-23
IL272237A (en) 2020-02-27
AU2021225160B2 (en) 2023-12-21
TW201940195A (zh) 2019-10-16
SMT201700515T1 (it) 2018-01-11
JP6190359B2 (ja) 2017-08-30
PE20141672A1 (es) 2014-11-26
ZA201308168B (en) 2018-11-28
AU2019216679A1 (en) 2019-09-05
JP7636651B2 (ja) 2025-02-27
IL305583A (en) 2023-10-01
BR112013028169A2 (pt) 2017-06-27
MX2019009244A (es) 2019-09-13
MY188820A (en) 2022-01-05
CA2834900A1 (en) 2012-11-08
CA2834900C (en) 2021-03-02
CN108969761A (zh) 2018-12-11
EA032625B1 (ru) 2019-06-28
CN108969469A (zh) 2018-12-11

Similar Documents

Publication Publication Date Title
ME02858B (me) Formulacija za anti- 4 7 antitelo
HRP20191299T1 (hr) Formulacije protutijela
ES2657226T3 (es) Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo
HRP20210342T1 (hr) Pripravci glikopeptida
HRP20201428T1 (hr) Stabilizirani pripravci koji sadrže anti-interleukin-6 receptorska (il-6r) antitijela
HRP20120903T4 (hr) Tekuća formulacija koja sadrži visoku koncentraciju protutijela
HRP20211343T1 (hr) Protutijela protiv dkk-1
JP2017533218A5 (me)
HRP20151215T1 (hr) Anti-nr10 protutijela i njihova uporaba
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
HRP20161311T1 (hr) Tekući farmaceutski pripravak
HRP20251036T1 (hr) Stabilna formulacija antitijela
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
HRP20200102T1 (hr) Formulacije protutijela anti-pdl1
HRP20150819T1 (hr) Derivati metastina i njihova uporaba
RU2012139181A (ru) Стабильная композиция, содержащая антитело
HRP20231578T1 (hr) Molekule protutijela na april i njihove uporabe
HRP20191827T1 (hr) Formulacija protutijela
ME02807B (me) HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE
HRP20130922T1 (hr) U potpunosti humana protutijela protiv humanog 4-1bb (cd137)
HRP20201268T1 (hr) Stabilne formulacije koje sadrže anti-pcsk9 antitijela
HRP20241131T1 (hr) Visokokoncentrirane formulacije inhibitornih antitijela masp-2 niske viskoznosti, pribori i metode
HRP20220811T1 (hr) Agonistička sredstva za vezanje tnf receptora
HRP20220692T1 (hr) Brzodjelujući pripravci inzulina
HRP20220011T1 (hr) Nova stabilna formulacija za fxia protutijela